Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. - Wikidata - awgldk - TriplyDB

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

http://www.wikidata.org/entity/Q33815701

about

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer Targeting tumor vasculature with an oncolytic virus.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.On the potential of oncolytic virotherapy for the treatment of canine cancers.Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Recent advances in oncolytic virus design.Oncolytic virotherapy Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.Oncolytic virotherapy: the questions and the promise.Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.Cancer: Tumour-fighting virus homes in.Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

P2860

Q26775030-C7C31717-AD6E-4767-A703-020A8EC055A9 Q27021839-AE60E1B7-83FC-465B-A6F1-87568F1F3208 Q30500348-A080779B-9979-483C-996E-5295D42E91FE Q33551626-352786D6-81CE-4A5E-97FA-FDFBE264D60C Q33820196-62A8FD1A-9AA3-47B1-80AB-51DB1387506B Q34473301-E018F3EF-803A-4449-A936-CDCDFB2371E8 Q34473352-D34BE482-294D-4A73-8360-A4AB46FDDB6D Q34662879-F6ED916A-285A-402E-B580-D1FD7B770C3B Q34763999-9D71E3DF-9000-40D2-A051-947ABB44802A Q35086690-99FAE6EE-3339-41B9-BC2B-00ADFB8D6F5E Q35596563-EB6E064A-A819-4760-BC0A-10DF5429C551 Q35623101-C5CF093A-C251-4521-8A25-BCBC6CB899BE Q35665220-A433DAB9-C90C-4F68-8B2D-ACEA8FBA51F4 Q35783456-BEC53621-B7CC-4BF3-B8B7-873E32F6F16F Q36574519-940A9EB6-7C4F-43F6-8626-97FE0BBFCA3B Q36582819-15F2409E-A083-4523-80C3-94131FE5FB25 Q36634430-B07A0A4C-3084-4DBC-8D15-E5B18D81C53C Q37031925-753473CB-2B35-426A-B7C9-41554EA759D4 Q37181377-AD8031F3-D927-4AA4-B9E0-0E2B8FFA7034 Q37477557-363B3F4D-2D22-4DCB-A486-F9750C011293 Q37865172-FDD78811-8E0F-41AC-8316-A40347681D65 Q38025263-F6B2303B-1A95-4BC6-9A59-4D2D02C09CDC Q38025696-7C929EBA-6F4C-4FA9-8822-CFC61734EE19 Q38223419-058A18F2-6D9A-43E8-B71A-4D8D92FB7AE4 Q38237657-A95EF5CB-1D97-4A06-AB32-A95ECC2694B1 Q38243811-D4AAA4F1-ACD8-42E8-A0D0-ABEDE9D7D3A2 Q38645375-C9230989-58A6-4FBC-A285-58D752629393 Q38647883-94D2B605-64D5-4B86-B215-91DC0FEB9F57 Q38924527-14FDBFE9-816B-47F1-A6B8-8F670A46E893 Q38962857-C196262E-F1B7-4547-B775-6715D88B9FA7 Q44623962-A495CA9F-1DBF-47F4-8D38-386B4CF3453F Q45363672-E70B4F36-AAF7-4132-9A8F-85EF7BA9F1A1 Q47781149-EA56AD25-F5B8-4050-AD8D-59BE473826C4 Q56986466-0A5FAD71-3B82-422C-8AD5-7B0A210B3CE3 Q57161784-16133169-744E-4393-B1CD-A40847898501

P2860

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

http://www.wikidata.org/entity/Q33815701

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antiangiogenic cancer therapy ...... of established tumors in mice.

@ast

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en-gb

type

label

Antiangiogenic cancer therapy ...... of established tumors in mice.

@ast

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en-gb

prefLabel

Antiangiogenic cancer therapy ...... of established tumors in mice.

@ast

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en-gb

P1433

Q33815701-1CD44F4B-1A88-419E-9979-39103A1127BA

P1476

Q33815701-174C663F-8065-4B53-AC8D-B641E8AADD0D

P2093

Q33815701-41BA8117-F07B-4460-BE32-E2F28B35248E

Q33815701-5205E54E-5C5A-401C-A6CA-912961DFAF0F

Q33815701-596C97FD-6EBC-4EEF-AD77-0BCF9C66D62A

Q33815701-79F637AD-7B9F-42E8-ADA6-5D611E3AD8E3

Q33815701-7A790216-618C-4F12-B455-F90E68601F06

Q33815701-7BB2FCB9-3552-4E4A-8C83-8587CD1F8E7D

Q33815701-7DCA3A95-A548-433E-9A80-43D103C97152

Q33815701-81CB57AE-9659-46E4-8D9A-33F0B32BD03D

Q33815701-BCF5C649-1020-41F7-BCDB-F507756549C0

Q33815701-D1961AC0-636B-47F8-9C7E-5752D3DF2724

P2860

Q33815701-17923EA1-7DEB-4FEB-9ECB-7C98AB1BAD47

Q33815701-17D7D472-8C73-4E13-8B6F-4563250B4AD3

Q33815701-198EEE16-9AAE-4FA9-B350-A1AF635E13B5

Q33815701-22A01809-B1E7-435B-9997-F89120C72B95

Q33815701-283405CB-6CC4-4ECB-A256-9A0EA6555244

Q33815701-2D94DEFA-69F9-4DD3-9F09-FAEB49DB1F41

Q33815701-2F591395-8768-4D5C-982C-7AD2AF8BD999

Q33815701-46AC426D-1356-45AC-8480-6D31034DAFE8

Q33815701-4D5A1127-8941-48E2-8919-EEDDE37B338A

Q33815701-53EECF2D-D507-4EE2-93BD-81325F7097B2

P304

Q33815701-967F4619-8C52-4F66-84D7-D0EAFB84CFD9

P31

Q33815701-999B7593-FE96-4FE3-A20F-E60493BD92F1

P356

Q33815701-3CA0DE88-0C96-4F09-9998-39ADACC92305

P407

Q33815701-723F2FF4-6252-4E35-B20C-0FB5D598A2E0

P433

Q33815701-954B1620-F29A-4D1D-AC01-92A2C73A1DD3

P478

Q33815701-E70F2A5E-B7BA-454F-ADA5-71F4A1195F7C

P50

Q33815701-18268604-7D7C-48C8-9002-F6CD13E891D2

Q33815701-89BEB5B6-7718-4949-A4B4-DCB30E4939DF

P577

Q33815701-EF7529AE-7D9E-4099-9D3C-B0F4F8A14937

P698

Q33815701-DDE11697-7987-4807-8631-D42DA5C901A0

P921

Q33815701-6C02BE11-375A-4DDE-A5B4-5A34F934581F

P932

Q33815701-100CF20C-50C2-415E-8626-9BB512CA848E

P356

P1433

Journal of Clinical Investigation

P1476

Antiangiogenic cancer therapy ...... of established tumors in mice.

@en

P2093

Geoff Hall

http://www.w3.org/2001/XMLSchema#string

Hardev Pandha

http://www.w3.org/2001/XMLSchema#string

Heung Chong

http://www.w3.org/2001/XMLSchema#string

Jill Thompson

http://www.w3.org/2001/XMLSchema#string

John Chester

http://www.w3.org/2001/XMLSchema#string

Jose Pulido

http://www.w3.org/2001/XMLSchema#string

Kevin Harrington

http://www.w3.org/2001/XMLSchema#string

Matt Coffey

http://www.w3.org/2001/XMLSchema#string

Richard Vile

http://www.w3.org/2001/XMLSchema#string

Rosa Maria Diaz

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Not all viruses are bad guys: the case for reovirus in cancer therapy.

P304

1551-1560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI41431

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20364090

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2860921

http://www.w3.org/2001/XMLSchema#string